Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7919115 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jan, 2029
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8840925 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(5 years from now) | |
US9339504 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(5 years from now) |
Market Authorisation Date: 08 May, 2009
Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9144547 | GLAXOSMITHKLINE LLC | Oral dosage form for controlled drug release |
Sep, 2023
(3 months from now) | |
US8637512 | GLAXOSMITHKLINE LLC | Formulations and method of treatment |
Jun, 2028
(5 years from now) |
Market Authorisation Date: 29 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
7
United Kingdom
4
China
4
Japan
4
United States
3
Korea, Republic of
3
European Union
2
Poland
2
Canada
2
Slovenia
2
Brazil
2
Hong Kong
2
Taiwan
2
Iceland
2
Morocco
2
Germany
2
Cyprus
2
Denmark
2
Argentina
2
Spain
2
Mexico
2
New Zealand
2
Australia
2
Colombia
2
Norway
2
South Africa
2
Austria
2
Portugal
2
Russia
2
Israel
2
Malaysia
1
Chile
1
Peru
1
Ukraine
1
AP
1
Uruguay
1
EA
1
OA
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic